Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554334 | 0.95 | GAA (0.34) | TSHRKMT2AGAACHRM2CHRM1 | |
| SCHEMBL15672479 | 0.86 | GAA (0.39) | ALDH1A1GAACHRM2CHRM1CHRM3 | |
| SCHEMBL19624382 | 0.83 | NAAA (0.37) | KMT2AALDH1A1MEN1GAA | |
| SCHEMBL16790834 | 0.82 | GAA (0.36) | GAACHRM2CHRM1CHRM3ADRA1A | |
| SCHEMBL19937260 | 0.81 | GAA (0.35) | GAACHRM2CHRM1CHRM3ADRA1A | |
| SCHEMBL19720347 | 0.81 | GAA (0.35) | GAACHRM2CHRM1CHRM3ADRA1A | |
| SCHEMBL19401234 | 0.80 | GAA (0.36) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL13554261 | 0.80 | GAA (0.36) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL16869880 | 0.80 | GAA (0.34) | GAACHRM2CHRM1CHRM3ADRA1A | |
| SCHEMBL19623163 | 0.79 | NAAA (0.34) | KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120268706-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120268706-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | NEFM, VIM, FLNB | TSHR 4504/4885KMT2A 4273/4885ALDH1A1 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.